Group 1 - A new round of QDII quotas has been approved, leading to a relaxation of purchase limits for several QDII funds, with 79 funds having adjusted their limits as of July 8 [1][4][6] - QDII funds focused on Hong Kong innovative pharmaceuticals and new consumption have achieved over 50% returns, while those targeting US stocks have seen close to 10% returns [1][8] - The overall valuation of Hong Kong stocks remains low compared to US stocks, suggesting that QDII funds investing in Hong Kong may continue to outperform those investing in the US [1][8][9] Group 2 - Several fund companies, including E Fund and Huaan Fund, have announced adjustments to their large purchase limits for QDII funds, significantly increasing the daily purchase limits for various funds [2][3] - As of July 8, 393 out of 675 QDII funds are either suspended from large purchases or in a closed period, indicating a significant portion of the market is still facing purchase restrictions [7] - The recent approval of $30.8 billion in new QDII investment quotas has alleviated some of the foreign exchange constraints faced by fund companies, although structural shortages in quotas still exist [4][6][7] Group 3 - The performance of QDII funds has been strong, with the best-performing fund, focused on Hong Kong innovative pharmaceuticals, showing a net value increase of 86.48% [8] - The valuation of US stocks has reached historical highs, with the Nasdaq index PE at 42.06 and the S&P 500 PE at 27.88, indicating potential risks for US stock investments [8] - Hong Kong stocks, particularly in high dividend and innovative pharmaceutical sectors, are viewed as having good investment opportunities due to their lower valuations, with the Hang Seng Index PE at 10.64 [9]

随着6月末国家外汇局新发放一批QDII额度，此前囿于额度从而限购、溢价的基金得以"解渴"，近期多只 QDII基金公告放宽限购额度，且部分场内ETF的溢价也有缓解之势。 作为QDII基金两大"去向"，港股与美股两大市场一直是投资焦点。半程行情落幕，港股QDII基金业绩大幅跑 赢美股相关产品，随着下半年行情开启，美股纳指、标普走出历史新高，港股当前估值仍然低于历史平均水 平，多家公募依旧旗帜鲜明地看好两大市场的投资前景。 多只QDII基金放宽限购额度 7月7日，易方达基金公告批量发布调整大额申购业务限制公告，调整旗下易方达标普医疗保健LOF、易方达信 息科技LOF、易方达生物科技LOF、易方达标普500LOF、易方达纳斯达克100ETF联接5只QDII的大额申购上 限。其中易方达纳斯达克100ETF联接单日申购上限从100元人民币调整至2000元，其余4只从100元调整至1000 元。 此外，近日华宝基金发布公告称，华宝致远混合型基金(QDII)将大额申购门槛由2万元调整为20万元，华宝纳 斯达克精选股票发起式(QDII)将大额申购门槛由5000元调整为2万元，华宝海外科技股票(QDII-LOF)将大额申 购门槛 ...

Group 1 - Multiple QDII funds have relaxed large subscription limits, indicating a positive shift in the market [1][5] - On July 4, Huabao Fund announced adjustments to the large subscription thresholds for several QDII products, significantly increasing the limits [2][4] - The recent changes in subscription limits are linked to the approval of a new round of QDII quotas [5][6] Group 2 - Huabao Fund's adjustments include raising the large subscription threshold for the Huabao Zhiyuan Mixed Fund from 20,000 RMB to 200,000 RMB [2][4] - Penghua Fund also announced an increase in subscription limits for its global high-yield bond fund, with the limit raised from 50,000 RMB to 100,000 RMB [4][5] - A total of 60 qualified domestic institutional investors received a combined new QDII quota of 21.2 billion USD, marking the first issuance in about a year [6][7]

【导读】多只QDII基金放宽大额申购限制 中国基金报记者 曹雯璟 多只QDII基金放宽大额申购限制。 7月4日， 鹏华、华宝 基金宣布旗下多只QDII基金产品调整大额申购金额上限。此外，近日， 华安、汇添富 等多家基金公司宣布旗下QDII 产品恢复正常申购业务或提升申购限制金额。 业内人士表示，多只 QDII产品恢复申购业务或大额申购，与新一轮QDII额度获批有关。 多只QDII基金放宽大额申购限制 7月4日，华宝基金发布公告称，华宝致远混合型基金(QDII)将大额申购门槛由2万元调整为20万元，华宝纳斯达克精选股票发起式(QDII)将 大额申购门槛由5000元调整为2万元，华宝海外科技股票(QDII-LOF)将大额申购门槛由2000元调整为1万元。 7月4日，鹏华基金也发布公告称，鹏华全球高收益债（QDII）人民币份额自7月7日起，单日单个基金账户累计申购和定期定额投资金额限 额由5万元调整为10万元。该基金美元现汇份额自7月7日起，单日单个基金账户累计申购和定期定额投资金额限额由1万美元调整为2万美 元。此外，鹏华全球中短债债券（QDII）也发布调整大额申购公告。 7月以来，多只QDII基金恢复了正常申购 ...